ReviewFrontiers in immunology2025

Cadonilimab as second-line therapy in immunotherapy-resistant squamous NSCLC: a case report and review.

Shuo Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.